Invivyd, Inc.
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company that discovers, develops and commercializes monoclonal antibody therapies for preventing and treating serious viral infectious diseases. Its lead authorized product, PEMGARDA (pemivibart), is an intravenous antibody authorized for pre-exposure prevention of… From the company’s description.
Over the twelve months to Jun 30, 2026, Invivyd, Inc. reported revenue of $58.37M, up 26.3% from a year earlier, and a net loss of $107.33M. Its operating margin was −192.8%, and operations used $108.42M in cash. In fiscal 2025, it reported revenue of $53.43M, up 110.5% from fiscal 2024, and a net loss of $52.49M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Invivyd, Inc. does
In the company’s own words
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company that discovers, develops and commercializes monoclonal antibody therapies for preventing and treating serious viral infectious diseases. Its lead authorized product, PEMGARDA (pemivibart), is an intravenous antibody authorized for pre-exposure prevention of COVID-19 in certain immunocompromised adults and adolescents who may not respond adequately to vaccination. The company markets PEMGARDA in the United States to healthcare practitioners and institutions serving these patients, including specialists in hematology, oncology, rheumatology and transplantation. Its pipeline includes VYD2311, a COVID-19 antibody candidate being evaluated in Phase 3 trials, and VBY329, a candidate for preventing respiratory syncytial virus infections in neonates, infants and children; it also investigates antibodies for measles and other viral diseases. Invivyd combines internal research and development with collaborations, including antibody discovery work with Adimab, while relying on outside contractors for clinical research and manufacturing. Its antibody discovery and development work began with a focus on COVID-19 and now extends to other infectious diseases.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- NEW HAVEN, CT
- Fiscal year end
- December
- CIK
- 1832038
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Invivyd, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Invivyd, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Invivyd, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Invivyd, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Invivyd, Inc.'s last four quarterly filings that the numbers alone won't show?”